Abstracts tagged "anti-TNF therapy"

Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Laurent Chanroux and Fara Mboge, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
Abstract Number: 3067 • 2016 ACR/ARHP Annual Meeting
Treatment Decisions Following Diagnosis of Cancer during TNFi Inhibitor Treatment in Patients with Rheumatoid Arthritis: Results from the BSRBR-RA
Katie Druce¹, Diederik Decock², Kath Watson¹, Deborah P.M. Symmons¹ and Kimme L. Hyrich¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Treatment Decisions Following Diagnosis of Cancer During TNFi inhibitor Treatment in Patients with Rheumatoid Arthritis: results from the BSRBR-RA Druce KL, De Cock D, Watson…
Abstract Number: 601 • 2016 ACR/ARHP Annual Meeting
Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept
Thierry Dervieux¹, Joel M. Kremer², Tyler O'Malley¹, Alan J Kivitz³, John Conklin⁴ and Michael Weinblatt⁵, ¹Research and Development, Exagen Diagnostics, Vista, CA, ²Albany Medical College, Albany, NY, ³Altoona Arthritis & Osteo Ctr, Duncansville, PA, ⁴1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁵Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Methotrexate (MTX) is known to improve exposure and clinical outcome to anti-tumor necrosis factor (TNF) therapy. While the precise mechanism of action for the…
Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Michael Weinblatt¹, Clifton Bingham III², Gerd-Rüdiger Burmester³, Vivian P. Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Ronald van Vollenhoven⁸, Brenda VanLunen⁹, Cécile Ecoffet¹⁰, Christopher Cioffi⁹ and Paul Emery¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
Abstract Number: 2472 • 2016 ACR/ARHP Annual Meeting
Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort
Ana C.M. Ribeiro¹, Karina Bonfiglioli², Renata Miossi², Carla G.S. Saad¹, Julio C. B. Moraes³, Mariana G Waisberg¹, Fernando Henrique Carlos de Souza¹, Nadia E Aikawa⁴, Leandro L. do Prado¹, Michelle Lopes¹, Luciana Seguro¹ and Eloisa Bonfá³, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Predictors of rheumatoid arthritis (RA) response to anti-TNF agents have been described. Except for certolizumab, the value of interim analysis before 24 weeks of…
Abstract Number: 3207 • 2016 ACR/ARHP Annual Meeting
The Deficiency of Adenosine Deaminase Type 2 (DADA2)—Results of Anti-TNF Treatment in a Cohort of Patients with a History of Stroke
Amanda K. Ombrello¹, Karyl Barron², Patrycja Hoffmann¹, Camilo Toro³, Deborah L. Stone⁴, Gineth Pinto-Patarroyo⁴, Anne Jones⁴, Tina Romeo⁵, Ariane Soldatos⁶, Qing Zhou⁷, Natalie Deuitch⁵, Jing Qin², Ivona Aksentijevich⁴ and Daniel L. Kastner⁴, ¹Inflammatory Diseases Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, ³NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁵National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ⁶National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, ⁷Inflammatory Disease Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The deficiency of adenosine deaminase type 2 (DADA2) is an autosomal recessive disease resulting from biallelic mutations in CECR1. Patients commonly present with vascular…
Abstract Number: 602 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching Between Certolizumab Pegol and Adalimumab after Primary Anti-TNF Treatment Failure: 2-Year Results from a Randomized, Investigator-Blind, Superiority Head-to-Head Study
Roy Fleischmann¹, Gerd-Rüdiger Burmester², Bernard Combe³, Jeffrey R. Curtis⁴, Stephen Hall⁵, Boulos Haraoui⁶, Ronald van Vollenhoven⁷, Christopher Cioffi⁸, Cécile Ecoffet⁹, Lucian Ionescu¹⁰, Leon Gervitz¹¹, Luke Peterson⁸ and Josef Smolen¹², ¹University of Texas Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, TX, ²Charité – University Medicine Berlin, Berlin, Germany, ³Montpellier University Hospital, Montpellier, France, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Cabrini Medical Centre, Monash University, Melbourne, Australia, ⁶Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Allée De La Recherche 60, UCB Pharma, Brussels, Belgium, ¹¹RA Patient Value Mission, UCB Pharma, Brussels, Belgium, ¹²Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: EULAR, ACR and treat-to-target guidelines recommend switching treatment in inadequate responders (IRs) to alternative therapy by Week (Wk) 12.1-3 Although any biological (b)DMARD can…
Abstract Number: 1046 • 2016 ACR/ARHP Annual Meeting
Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures
Lars Rogge¹, Silvia Menegatti², Eleonora Latis¹, Elena Mascia¹, Hanane Yahia¹, Claire Leloup¹, Anna Molto³, Corinne Miceli-Richard⁴, Maxime Dougados^5,6 and Elisabetta Bianchi¹, ¹Immunology, Institut Pasteur, Paris, France, ²Immunology, Immunoregulation Unit, Institut Pasteur, Paris, France, ³Hopital Cochin, Paris Descartes University, Paris, France, ⁴Rheumatology, Hôpital Cochin, Paris, France, ⁵Paris Descartes University, Paris, France, ⁶Service de Rhumatologie B, Hopital Cochin, Paris, France
Background/Purpose: The introduction of anti-TNF therapy has proven effective to reduce inflammation and clinical symptoms in several chronic inflammatory diseases. However, TNF-blockers are effective only…
Abstract Number: 2535 • 2016 ACR/ARHP Annual Meeting
Effect of Methotrexate in the Presence of Drug and the Appearance of Antibodies Against Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Chamaida Plasencia-Rodriguez¹, Ana Martínez², Alejandro Villalba³, Teresa Jurado⁴, Eva Olariaga-Merida⁵, Araceli Mezcua⁶, Diana Peiteado³, Gema Bonilla³, Laura Nuño³, Alejandro Balsa¹ and Dora Pascual-Salcedo², ¹Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain, ²Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ³Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁴Immunology Unit, La Paz University Hospital-IdiPaz, MADRID, Spain, ⁵Immunology, University Hospital La Paz, Madrid, Spain, ⁶Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: Several factors influence pharmacokinetics of TNFinhibitors (TNFi). One relevant factor is the formation of anti drug- antibodies (ADA) associated with low drug levels and…
Abstract Number: 3226 • 2016 ACR/ARHP Annual Meeting
Maintenance of Clinical Remission and Radiographic Non-Progression with MTX after Completion of 1 Year Initial Treatment with Certolizumab Pegol in Japanese Patients with Early Rheumatoid Arthritis
Yoshiya Tanaka¹, Tatsuya Atsumi², Kazuhiko Yamamoto³, Tsutomu Takeuchi⁴, Hisashi Yamanaka⁵, Naoki Ishiguro⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Pauline Ralston¹¹, Désirée van der Heijde¹², Nobuyuki Miyasaka^13,14 and Takao Koike¹⁵, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³The University of Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁵Tokyo Women's Medical University, Tokyo, Japan, ⁶Nagoya University, Nagoya, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan, ⁸Tohoku University, Sendai, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰UCB Pharma, Tokyo, Japan, ¹¹Hays Pharma, London, United Kingdom, ¹²Leiden University Medical Center, Leiden, Netherlands, ¹³Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁴Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵Sapporo Medical Center NTT EC, Sapporo, Japan
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) treatment in combination with dose-optimized MTX in Japanese MTX-naïve early RA patients (pts) with poor prognostic…
Abstract Number: 605 • 2016 ACR/ARHP Annual Meeting
Assessment of Comparative Immunogenicity in Biosimilar Development: Immunogenicity and Pharmacokinetics Following a Single Dose of M923, a Proposed Biosimilar for Reference Adalimumab (HUMIRA®), Compared with US- and EU-Sourced Reference Adalimumab in Healthy Subjects
Jan Hillson¹, Tim Mant², Tanmoy Ganguly³, William Avery³, Molly Rosano³, Carolyn Huntenburg³, Donna Palmer⁴, Siddesh Darne⁴, Borislava Pavlova⁴, Jennifer Doralt⁴, Russell Reeve⁵, Niti Goel⁵, Doris Weilert⁵, Paul Rhyne⁶, John Caminis⁴ and James Roach³, ¹Clinical Research, Momenta Pharmaceuticals, Inc., Cambridge, MA, ²Quintiles Drug Research Unit at Guy's Hospital, London, London, United Kingdom, ³Momenta Pharmaceuticals, Inc., Cambridge, MA, ⁴Shire, Cambridge, MA, ⁵Quintiles, Inc., Durham, NC, ⁶Q2 Solutions, Marietta, GA
Background/Purpose: 324 healthy volunteers were randomized 1:1:1 to receive a single 40 mg dose of M923, US-sourced reference adalimumab, or EU-sourced reference adalimumab by subcutaneous…
Abstract Number: 1338 • 2016 ACR/ARHP Annual Meeting
Use of Subcutaneous Golimumab in Autoimmune Inner Ear Disease
Deeba Minhas¹, Michele Gandolfi², Jennifer Derebery³, Eric Wilkinson³ and Mariko Ishimori¹, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Otology, House Clinic, Los Angeles, CA, ³House Clinic, Los Angeles, CA
Background/Purpose: Autoimmune Inner Ear Disease (AIED) is characterized by rapidly progressive sensorineural hearing loss accompanied by tinnitus, with or without vertigo, which may progress to…
Abstract Number: 2588 • 2016 ACR/ARHP Annual Meeting
The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Leslie R. Harrold^1,2, Heather J. Litman¹, Katherine C. Saunders¹, Kimberly J. Dandreo¹, Bernice Gershenson², Jeffrey D. Greenberg^1,3, Robert Low⁴, Jeffrey Stark⁴, Robert Suruki⁴, Srihari Jaganathan⁴ and Mohamed Yassine⁴, ¹Corrona, LLC, Southborough, MA, ²University of Massachusetts Medical School, Worcester, MA, ³NYU School of Medicine, New York, NY, ⁴UCB Pharma, Smyrna, GA
Background/Purpose: To examine the association of cardiovascular, malignant and serious infection events (SIEs) with certolizumab pegol (CZP) use as compared to other TNFi agents in…
Abstract Number: 609 • 2016 ACR/ARHP Annual Meeting
Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)
Yoshiya Tanaka¹, Kiyotaka Yamazaki², Ryo Nakajima², Shuichi Komatsu³, Naoki Agata⁴, Ataru Igarashi⁵, Toshiro Tango⁶ and Tsutomu Takeuchi⁷, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ³Scientific Project Manager Group, Medical, AbbVie GK, Tokyo, Japan, ⁴Medical Communication, Medical, AbbVie GK, Tokyo, Japan, ⁵Department of Drug Policy & Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan, ⁶Center for Medical Statistics, Tokyo, Japan, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Patients with Rheumatoid Arthritis (RA) experience loss of productivity such as missing their work and lowering their performance incurred by impaired physical functioning. Treatment…
Abstract Number: 1364 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tumour Necrosis Factor Antagonists in a Large Cohort of Juvenile Dermatomyositis Patients
Raquel Campanilho-Marques^1,2,3,4, Claire Deakin⁵, Stephanie Simou⁶, Lucy R Wedderburn^2,7,8, Clarissa Pilkington^7,9 and on behalf of Juvenile Dermatomyositis Research Group (JDRG), ¹Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, Portugal, ²Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ³Rheumatology, Santa Maria Hospital, CHLN, Lisbon, Portugal, ⁴Rheumatology, Instituto Português de Reumatologia, Lisbon, Portugal, ⁵Infection, Inflammation and Rheumatology Section,, UCL Institute of Child Health, London, United Kingdom, ⁶Infection, Inflammation and Rheumatology, UCL Institute of Child Health, London, United Kingdom, ⁷Infection, Inflammation and Rheumatology Section, UCL Institute of Child Health, London, United Kingdom, ⁸Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁹Paediatric Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom
Background/Purpose: Some patients with juvenile dermatomyositis (JDM) have a disease course which is refractory to multiple drug treatments. There is evidence that prolonged disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.